Medium-Dose Inhaled Corticosteroid (ICS) Medications
Medium-dose ICS refers to a daily dose range of >250 to 500 μg of fluticasone propionate or its equivalent in other ICS molecules. This dosing category is used in Step 3 and Step 4 asthma management according to NAEPP guidelines 1.
Specific Medium-Dose ICS Equivalents
The guidelines reference medium-dose ICS primarily in the context of fluticasone propionate equivalents, with the medium-dose range defined as:
- >250 to 500 μg/day of fluticasone propionate (or equivalent)
This translates to comparable doses across different ICS molecules, though the evidence provided focuses on:
- Fluticasone propionate: >250-500 μg/day
- Budesonide: Equivalent medium-dose range (specific μg not detailed in these guidelines but proportionally higher than fluticasone)
- Mometasone: Medium-dose range (used in Step 3-4 therapy) 1
- Beclomethasone HFA: Medium-dose equivalent
- Ciclesonide: Medium-dose equivalent
Clinical Context for Medium-Dose ICS Use
Medium-dose ICS is recommended as monotherapy in Step 3 care for moderate persistent asthma as an alternative to low-dose ICS plus LABA 1. The guidelines specify this is a preferred option alongside combination therapy.
In Step 4 care, medium-dose ICS is combined with a long-acting beta-agonist (LABA) as the preferred treatment for more severe persistent asthma 1.
Key Clinical Considerations:
For children under 5 years: Medium-dose ICS monotherapy is a preferred option for moderate persistent asthma, given concerns about systemic effects at higher doses and limited data on LABAs in this age group 2
Dose-response relationship: The evidence shows that approximately 80-90% of maximum ICS benefit is achieved at what guidelines currently classify as "low dose" (200-250 μg fluticasone equivalent), with diminishing returns and increased systemic side effects at medium and high doses 3
Growth effects in children: A dose-dependent reduction in growth velocity occurs with increasing ICS doses, with medium doses showing measurable effects on linear growth (mean difference of 0.20 cm/year between low and medium doses) 4
Important Caveats
The terminology of "low," "medium," and "high" dose ICS has been challenged as not evidence-based, with some experts proposing that what is currently called "low dose" should be considered the "standard dose" since it achieves most therapeutic benefit 3. This suggests that medium-dose ICS should be reserved for situations where lower doses have proven inadequate, rather than being a routine step-up.
When stepping up from low-dose ICS, adding a LABA to low-dose ICS is generally preferred over increasing to medium-dose ICS monotherapy in patients 12 years and older, based on superior efficacy for most outcomes 5, 1, 5.